Published on 10 May 2024 on Zacks via Yahoo Finance
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
bluebird bio BLUE registered revenues of $18.6 million in the first quarter, up from $2.4 million recorded in the year-ago quarter and beating the Zacks Consensus Estimate of $18 million.
The $16.2-million upside can be attributed to increased Zynteglo product revenues.
The FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusion on Aug 17, 2022, and Skysona for treating early, active cerebral adrenoleukodystrophy (CALD) on Sept 16, 2022.